ImmunityBio (IBRX) Stock Overview
A commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
IBRX Community Fair Values
Create NarrativeSee what 36 others think this stock is worth. Follow their fair value or set your own to get alerts.
ImmunityBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.90 |
| 52 Week High | US$7.63 |
| 52 Week Low | US$1.83 |
| Beta | -0.065 |
| 1 Month Change | 44.28% |
| 3 Month Change | -3.33% |
| 1 Year Change | -52.38% |
| 3 Year Change | -25.06% |
| 5 Year Change | n/a |
| Change since IPO | -92.51% |
Recent News & Updates
Recent updates
ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish
Apr 29ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
Mar 07Earnings Update: ImmunityBio, Inc. (NASDAQ:IBRX) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts
Mar 06
ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval
Jan 17ImmunityBio's Cash Burn And Dilution Dampen Anktiva's Potential
Dec 11ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful
Oct 25ImmunityBio: Moving The Needle
Oct 07ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt
Sep 21ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'
Aug 14ImmunityBio: All Eyes On Execution Now (Rating Upgrade)
Jul 09ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential
Jun 25ImmunityBio: Anktiva's Launch Demands A Reassessment
Jun 06ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle
Apr 23ImmunityBio: Financial And Regulatory Risks Outweigh Anktiva's Promise
Feb 27ImmunityBio: Buy Low Now Vs. Buy High Later
Feb 11Shareholder Returns
| IBRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 11.5% | -0.04% | 0.8% |
| 1Y | -52.4% | -12.1% | 11.0% |
Return vs Industry: IBRX underperformed the US Biotechs industry which returned -12.1% over the past year.
Return vs Market: IBRX underperformed the US Market which returned 11% over the past year.
Price Volatility
| IBRX volatility | |
|---|---|
| IBRX Average Weekly Movement | 13.4% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: IBRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IBRX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 671 | Rich Adcock | immunitybio.com |
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors.
ImmunityBio, Inc. Fundamentals Summary
| IBRX fundamental statistics | |
|---|---|
| Market cap | US$2.59b |
| Earnings (TTM) | -US$409.10m |
| Revenue (TTM) | US$31.22m |
Is IBRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBRX income statement (TTM) | |
|---|---|
| Revenue | US$31.22m |
| Cost of Revenue | US$58.00k |
| Gross Profit | US$31.16m |
| Other Expenses | US$440.27m |
| Earnings | -US$409.10m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 99.81% |
| Net Profit Margin | -1,310.30% |
| Debt/Equity Ratio | -132.4% |
How did IBRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/05 06:14 |
| End of Day Share Price | 2025/06/05 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ImmunityBio, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Zelin | BTIG |
| Jason Kolbert | D. Boral Capital LLC. |
| Andres Maldonado | H.C. Wainwright & Co. |